GlaxoSmithKline Plc (GSK)

40.89
0.14 0.34
NYSE : Health Technology
Prev Close 41.03
Open 40.59
Day Low/High 40.48 / 41.09
52 Wk Low/High 31.43 / 48.25
Volume 1.62M
Avg Volume 5.19M
Exchange NYSE
Shares Outstanding 2.51B
Market Cap 101.99B
EPS 2.40
P/E Ratio 23.74
Div & Yield 1.97 (4.76%)

GlaxoSmithKline downgraded at UBS

They Just Don't Get Glaxo!

They Just Don't Get Glaxo!

Marek Fuchs, senior contributing analyst at TheStreet, talks proportion on Glaxo.

Pipeline Full, Dividend Secure, Says Glaxo CFO

Pipeline Full, Dividend Secure, Says Glaxo CFO

Simon Dingemans, CFO of GlaxoSmithKline, discusses the company's bid for Human Genome, Obamacare and the company's growing emerging-market business.

Auxilium On a Roll with Xiaflex, Testim Deal

Auxilium On a Roll with Xiaflex, Testim Deal

Adrian Adams, CEO of Auxilium, discusses the company's breakthrough with Xiaflex, as well as recent news surrounding its drug Testim.

Biotech Breakout

Biotech Breakout

SPDR S&P Biotech ETF is likely to post new highs in the second quarter.

GlaxoSmithKline Takes Human Genome Bid Hostile: Hot Trends

GlaxoSmithKline Takes Human Genome Bid Hostile: Hot Trends

A look at the day's most searched trends on the Web, including GlaxoSmithKline's intentions to take its bid for Human Genome Sciences hostile.

The Next Big Thing in Biotech: M&A

The Next Big Thing in Biotech: M&A

Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.

Three Cheap Speculative Bets

Three Cheap Speculative Bets

Aviat, Capstone and Axcelis are high-reward/high-risk plays for under $2.50.

EU OKs J&J's $21.3B Synthes Takeover: Hot Trends

EU OKs J&J's $21.3B Synthes Takeover: Hot Trends

A look at the day's most searched topics on the Web, including the European Union's approval of Johnson & Johnson's $21.3 billion takeover of Synthes.

Playing in Biotech -- A Primer

Playing in Biotech -- A Primer

Biotech is changing, so here's how to invest amid the industry's new gold rush.

Safe Stocks for Your Income Portfolio

Safe Stocks for Your Income Portfolio

If you need to live on investment income, bonds and CDs are not enough -- you need dividends.

Ligand Pharma Still Worth a Shot

Ligand Pharma Still Worth a Shot

The damage to a big drug's approval odds is much less than is presently priced into LGND.